Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor

Toxicological Sciences

Volumn 120, Issue 2, 2011, Pages 269-283

  Guha, Mausumee ^a,d   Heier, Annabelle ^b   Price, Sally ^b   Bielenstein, Margareta ^c   Caccese, Robert G ^a   Heathcote, Daniel I ^b   Simpson, Thomas R ^a,e   Stong, David B ^a,f   Bodes, Elmarie ^a  

^a ASTRAZENECA   (United Kingdom)

^b Safety Assessment Alderley Park   (United Kingdom)

^c Clinical Pharmacology   (Sweden)

^d Drug Safety Evaluation   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Brandywine Hospital   (United States)

Author keywords

Biomarkers; Cynomolgus monkey; Drug induced kidney toxicity; Multiplex immunoassays; Triple reuptake inhibitor

Indexed keywords

3 METHYLAMINO 2 (2 NAPHTHYL) 1 PHENYL 1 PROPANOL; AQUAPORIN 1; AQUAPORIN 2; BIOLOGICAL MARKER; CALBINDIN; CLUSTERIN; PRC 200 SS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY INJURY; LOW DRUG DOSE; MACACA FASCICULARIS; MALE; NEPHROTOXICITY; NONHUMAN; URINALYSIS;

MACACA FASCICULARIS; RATTUS;

EID: 79953110651     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr013     Document Type: Article

References (38)

1. Aleksunes, L.M., Goedken,M. J., Rockwell, C. E., Thomale, J.,Manautou, J. E., and Klaassen, C. D. (2010). Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatininduced nephrotoxicity. J. Pharmacol. Exp. Ther. 335, 2-12.
2. Allen, N. B., Hetrick, S. E., Simmons, J. G., and Hickie, I. B. (2007). Early intervention for depressive disorders in young people: the opportunity and the (lack of) evidence. Med. J. Aust. 187, S15-S17.
3. Arany, I., and Safirstein, R. L. (2003). Cisplatin nephrotoxicity. Semin. Nephrol. 23, 460-464.
4. Baer, P. C., Bereiter-Hahn, J., Schubert, R., and Geiger, H. (2006). Differentiation status of human renal proximal and distal tubular epithelial cells in vitro: differential expression of characteristic markers. Cells Tissues Organs 184, 16-22.
5. Bonventre, J. V., Vaidya, V. S., Schmouder, R., Feig, P., and Dieterle, F. (2010). Next-generation biomarkers for detecting kidney toxicity. Nat. Biotechnol. 28, 436-440.
6. Bouman, C. S., Forni, L. G., and Joannidis, M. (2010). Biomarkers and acute kidney injury: dining with the Fisher King? Intensive Care Med. 36, 381-384.
7. Chang, C. H., Lin, C. Y., Tian, Y. C., Jenq, C. C., Chang, M. Y., Chen, Y. C., Fang, J. T., and Yang, C. W. (2010). Acute kidney injury classification: comparison of AKIN and RIFLE criteria. Shock 33, 247-252.
8. Chen, Z., and Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin. Investig. Drugs 16, 1365-1377.
9. Chetty, R. K., Ozer, J. S., Lanevschi, A., Schuppe-Koistinen, I., McHale, D., Pears, J. S., Vonderscher, J., Sistare, F. D., and Dieterle, F. (2010). A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association. Clin. Pharmacol. Ther. 88, 260-262.
10. Dieterle, F., Perentes, E., Cordier, A., Roth, D. R., Verdes, P., Grenet, O., Pantano, S., Moulin, P., Wahl, D., Mahl, A., et al. (2010a). Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect druginduced kidney injury. Nat. Biotechnol. 28, 463-469.
11. Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J. S., Webb, C. P., Baer, W., Senagore, A., Schipper, M. J., Vonderscher, J., et al. (2010b). Renal biomarker qualification submission: a dialog between the FDAEMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 28, 455-462.
12. DuBose, T. D., Jr. (1990). Experimental models of distal renal tubular acidosis. Semin. Nephrol. 10, 174-180.
13. European Medicines Agency (EMA). (2010). Consultation on the Qualification Opinion ILSI/HESI Submission of Novel Renal Biomarkers for Toxicity 30 April 2010. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/05/WC500090466.pdf. Accessed November 17, 2010.
14. Ferguson, M. A., Vaidya, V. S., and Bonventre, J. V. (2008). Biomarkers of nephrotoxic acute kidney injury. Toxicology 245, 182-193.
15. Gobé, G. C., Buttyan, R., Wyburn, K. R., Etheridge, M. R., and Smith, P. J. (1995). Clusterin expression and apoptosis in tissue remodeling associated with renal regeneration. Kidney Int. 47, 411-420.
16. Hoffmann, D., Adler, M., Vaidya, V. S., Rached, E., Mulrane, L., Gallagher, W. M., Callanan, J. J., Gautier, J. C., Matheis, K., Staedtler, F., et al. (2010). Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol. Sci. 116, 8-22.
17. Kumar, R., Schaefer, J., Grande, J. P., and Roche, P. C. (1994). Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am. J. Physiol. 266, 477-485.
18. Liang, Y., Shaw, A. M., Boules, M., Briody, S., Robinson, J., Oliveros, A., Blazar, E., Williams, K., Zhang, Y., Carlier, P. R., et al. (2008). Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J. Pharmacol. Exp. Ther. 327, 573-583.
19. Marrer, E., and Dieterle, F. (2010). Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol. 243, 167-179.
20. McDonough, A. A. (2010). Mechanisms of proximal tubule sodium transport regulation that link extracellular fluid volume and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R851-R861.
21. McIlroy, D. R., Wagener, G., and Lee, H. T. (2010). Biomarkers of acute kidney injury: an evolving domain. Anesthesiology 112, 998-1004.
22. Mehta, R. L. (2010). Timed and targeted therapy for acute kidney injury: a glimpse of the future. Kidney Int. 77, 947-949.
23. Moriates, C., and Maisel, A. (2010). The utility of biomarkers in sorting out the complex patient. Am. J. Med. 123, 393-399.
24. Nielsen, S., DiGiovanni, S. R., Christensen, E. I., Knepper, M. A., and Harris, H. W. (1993). Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc. Natl. Acad. Sci. U.S.A. 90, 11663-11667.
25. Opperman, L. A., Pettifor, J. M., and Ross, F. P. (1990). Immunohistochemical localization of calbindins (28K and 9K) in the tissues of the baboon Papio ursinus. Anat. Rec. 228, 425-430.
26. Ozer, J. S., Dieterle, F., Troth, S., Perentes, E., Cordier, A., Verdes, P., Staedtler, F., Mahl, A., Grenet, O., Roth, D. R., et al. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 28, 486-494.
27. Skolnick, P., Krieter, P., Tizzano, J., Basile, A., Popik, P., Czobor, P., and Lippa, A. (2006). Preclinical and clinical pharmacology of DOV 216,303, a 'triple' uptake inhibitor. CNS Drug Rev. 12, 123-134.
28. Sieber, M., Hoffmann, D., Adler, M., Vaidya, V. S., Clement, M., Bonventre, J. V., Zidek, N., Rached, E., Amberg, A., Callanan, J. J., et al. (2009). Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 109, 336-349.
29. Sinha, G. (2007). European Union creates its own "critical path". J. Natl. Cancer Inst. 99, 832-833.
30. Sourial, S., Searchfield, L., Schuppe-Koistinen, I., Betton, G. R., Riccardi, D., and Price, S. A. (2010). Application of Dolichos biflorus in immunoassay detection of kidney collecting duct biomarkers. Biomarkers 15, 424-435.
31. Srisawat, N., Murugan, R., Wen, X., Singbartl, K., Clermont, G., Eiam-Ong, S., and Kellum, J. A. (2010). Recovery from acute kidney injury: determinants and predictors. Contrib. Nephrol. 165, 284-291.
32. Takashi, M., Zhu, Y., Miyake, K., and Kato, K. (1996). Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol. Int. 56, 174-179.
33. Thukral, S. K., Nordone, P. J., Hu, R., Sullivan, L., Galambos, E., Fitzpatrick, V. D., Healy, L., Bass, M. B., Cosenza, M. E., and Afshari, C. A. (2005). Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33, 343-355.
34. Tonomura, Y., Tsuchiya, N., Torii, M., and Uehara, T. (2010). Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 273, 53-59.
35. Vaidya, V. S., Ferguson, M. A., and Bonventre, J. V. (2008a). Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. 48, 463-493.
36. Vaidya, V. S., Waikar, S. S., Ferguson, M. A., Collings, F. B., Sunderland, K., Gioules, C., Bradwin, G., Matsouaka, R., Betensky, R. A., Curhan, G. C., et al. (2008b). Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin. Transl. Sci. 1, 200-208.
37. Werner, M., Costa, M. J., Mitchell, L. G., and Nayar, R. (1995). Nephrotoxicity of xenobiotics. Clin. Chim. Acta 237, 107-154.
38. Zhai, X. Y., Fenton, R. A., Andreasen, A., Thomsen, J. S., and Christensen, E. I. (2007). Aquaporin-1 is not expressed in descending thin limbs of short-loop nephrons. J. Am. Soc. Nephrol. 18, 2937-2944.